Your browser doesn't support javascript.
loading
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study.
Pagliari, Maria Teresa; Rosendaal, Frits R; Ahmadinejad, Minoo; Badiee, Zahra; Baghaipour, Mohammad-Reza; Baronciani, Luciano; Benítez Hidalgo, Olga; Bodó, Imre; Budde, Ulrich; Castaman, Giancarlo; Eshghi, Peyman; Goudemand, Jenny; Karimi, Mehran; Keikhaei, Bijan; Lassila, Riitta; Leebeek, Frank W G; Lopez Fernandez, Maria Fernanda; Mannucci, Pier Mannuccio; Marino, Renato; Oldenburg, Johannes; Peake, Ian; Santoro, Cristina; Schneppenheim, Reinhard; Tiede, Andreas; Toogeh, Gholamreza; Tosetto, Alberto; Trossaert, Marc; Yadegari, Hamideh; Zetterberg, Eva M K; Peyvandi, Flora; Federici, Augusto B; Eikenboom, Jeroen.
Afiliación
  • Pagliari MT; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Rosendaal FR; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Ahmadinejad M; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
  • Badiee Z; Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Baghaipour MR; Hemophilia-Thalassemia Center, Mashhad University of Medical Science, Mashad, Iran.
  • Baronciani L; Iranian Hemophilia Comprehensive Treatment Centre, Tehran, Iran.
  • Benítez Hidalgo O; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
  • Bodó I; Hemophilia Unit,Hematology Department, Hospital Universitari Vall d'Hebron, Spain.
  • Budde U; Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.
  • Castaman G; Hemostaseology Medilys Laborgesellschaft mbH, Hamburg, Germany.
  • Eshghi P; Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.
  • Goudemand J; Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Karimi M; Department of Hematology and Transfusion, CHU Lille, University of Lille, Lille, France.
  • Keikhaei B; Hematology Research Center,Nemazee Hospital, Shiraz University of Medical Science, Shiraz, Iran.
  • Lassila R; Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Leebeek FWG; Research Program Unit in Oncology, University of Helsinki, Helsinki University Central Hospital, Coagulation Disorders, Helsinki, Finland.
  • Lopez Fernandez MF; Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Mannucci PM; Complejo Hospitalario Universitario de A Coruña-Servicio de Hematología y Hemoterapia, A Coruña, Spain.
  • Marino R; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
  • Oldenburg J; Hemophilia and Thrombosis Centre, University Hospital Policlinico, Bari, Italy.
  • Peake I; Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany.
  • Santoro C; Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom.
  • Schneppenheim R; Hematology, Hemophilia and Thrombosis Center, University Hospital Policlinico Umberto I, Rome, Italy.
  • Tiede A; Department of Pediatric Hematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
  • Toogeh G; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Tosetto A; Thrombosis Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Trossaert M; Hemophilia and Thrombosis Center, Hematology Department, San Bortolo Hospital, Vicenza, Italy.
  • Yadegari H; Centre Régional de Traitement de l'Hémophilie-Laboratoire d'Hématologie, Nantes, France.
  • Zetterberg EMK; Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany.
  • Peyvandi F; Skane University Hospital, Malmo, Sweden.
  • Federici AB; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
  • Eikenboom J; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
J Thromb Haemost ; 20(5): 1106-1114, 2022 05.
Article en En | MEDLINE | ID: mdl-35092343
ABSTRACT

BACKGROUND:

Type 3 von Willebrand disease (VWD) is a severe bleeding disorder caused by the virtually complete absence of von Willebrand factor (VWF). Pathophysiological mechanisms of VWD like defective synthesis, secretion, and clearance of VWF have previously been evaluated using ratios of VWF propeptide (VWFpp) over VWF antigen (VWFAg) and factor (F)VIII coagulant activity (FVIIIC) over VWFAg.

OBJECTIVE:

To investigate whether the VWFpp/VWFAg and FVIIIC/VWFAg ratios may also be applied to understand the pathophysiological mechanism underlying type 3 VWD and whether VWFpp is associated with bleeding severity.

METHODS:

European and Iranian type 3 patients were enrolled in the 3WINTERS-IPS study. Plasma samples and buffy coats were collected and a bleeding assessment tool was administered at enrolment. VWFAg, VWFpp, FVIIIC, and genetic analyses were performed centrally, to confirm patients' diagnoses. VWFpp/VWFAg and FVIIIC/VWFAg ratios were compared among different variant classes using the Mann-Whitney test. Median differences with 95% confidence intervals (CI) were estimated using the Hodges-Lehmann method. VWFpp association with bleeding symptoms was assessed using Spearman's rank correlation.

RESULTS:

Homozygosity/compound heterozygosity for missense variants showed higher VWFpp level and VWFpp/VWFAg ratio than homozygosity/compound heterozygosity for null variants ([VWFpp median difference, 1.4 IU/dl; 95% CI, 0.2-2.7; P = .016]; [VWFpp/VWFAg median difference, 1.4; 95% CI, 0-4.2; P = .054]). FVIII C/VWFAg ratio was similarly increased in both. VWFpp level did not correlate with the bleeding symptoms (r = .024; P = .778).

CONCLUSIONS:

An increased VWFpp/VWFAg ratio is indicative of missense variants, whereas FVIIIC/VWFAg ratio does not discriminate missense from null alleles. The VWFpp level was not associated with the severity of bleeding phenotype.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades de von Willebrand / Enfermedad de von Willebrand Tipo 3 Tipo de estudio: Diagnostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: J Thromb Haemost Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades de von Willebrand / Enfermedad de von Willebrand Tipo 3 Tipo de estudio: Diagnostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: J Thromb Haemost Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Italia